XTX Topco Ltd Buys 3,787 Shares of Amgen Inc. (NASDAQ:AMGN)

XTX Topco Ltd increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 179.1% during the 3rd quarter, Holdings Channel reports. The fund owned 5,902 shares of the medical research company’s stock after buying an additional 3,787 shares during the quarter. XTX Topco Ltd’s holdings in Amgen were worth $1,902,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Zacks Investment Management acquired a new stake in Amgen in the third quarter worth $31,776,000. Zega Financial LLC bought a new stake in shares of Amgen in the 3rd quarter valued at $1,032,000. Zimmer Partners LP acquired a new stake in Amgen during the 3rd quarter worth $5,800,000. Zurich Insurance Group Ltd FI lifted its holdings in Amgen by 3.5% during the third quarter. Zurich Insurance Group Ltd FI now owns 130,288 shares of the medical research company’s stock worth $41,980,000 after acquiring an additional 4,402 shares in the last quarter. Finally, iA Global Asset Management Inc. lifted its holdings in Amgen by 3.9% during the third quarter. iA Global Asset Management Inc. now owns 54,774 shares of the medical research company’s stock worth $17,649,000 after acquiring an additional 2,077 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Royal Bank of Canada dropped their price target on Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 27th. Robert W. Baird reissued an “underperform” rating and set a $215.00 target price on shares of Amgen in a research note on Wednesday, September 25th. William Blair reaffirmed an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Sanford C. Bernstein began coverage on shares of Amgen in a report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price target for the company. Finally, Leerink Partners dropped their price objective on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $323.05.

Amgen Stock Down 0.6 %

NASDAQ:AMGN opened at $272.58 on Friday. The firm has a market capitalization of $146.52 billion, a price-to-earnings ratio of 34.90, a price-to-earnings-growth ratio of 3.08 and a beta of 0.55. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. Amgen Inc. has a twelve month low of $257.80 and a twelve month high of $346.85. The stock’s 50 day moving average price is $306.58 and its two-hundred day moving average price is $315.82.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the previous year, the company earned $4.96 earnings per share. Equities research analysts expect that Amgen Inc. will post 19.51 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be paid a $2.25 dividend. The ex-dividend date is Monday, November 18th. This represents a $9.00 annualized dividend and a yield of 3.30%. Amgen’s dividend payout ratio (DPR) is currently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.